|
FR104E
(fr)
|
|
|
|
|
|
US5843708A
(en)
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
|
ES2052027T5
(es)
|
1988-11-11 |
2005-04-16 |
Medical Research Council |
Clonacion de secuencias de dominio variable de inmunoglobulina.
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
AU7579291A
(en)
|
1990-04-16 |
1991-11-11 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Use of purinergic receptor agonists as antineoplastic agents
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5900407A
(en)
|
1997-02-06 |
1999-05-04 |
Inspire Pharmaceuticals, Inc. |
Method of treating dry eye disease with uridine triphosphates and related compounds
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
DE19939653A1
(de)
|
1999-08-13 |
2001-02-22 |
Thomas Huenig |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
|
DE60035057T2
(de)
|
1999-10-04 |
2008-01-31 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
CD40 Antagonist zur Behandlung von Psoriasis
|
|
CN1413113A
(zh)
|
1999-12-22 |
2003-04-23 |
印斯拜尔药品股份有限公司 |
使用嘌呤能受体激动剂治疗胃肠道疾病的方法
|
|
EP1261376A1
(fr)
|
2000-01-27 |
2002-12-04 |
Genetics Institute, LLC |
Anticorps contre ctla4 (cd152), conjugues comprenant lesdits anticorps, et leurs utilisations
|
|
BR0110190A
(pt)
|
2000-04-19 |
2003-12-30 |
Tanox Inc |
Antagonistas de cd40 para uso em tratamento de psorìase e outras condições inflamatórias de pele
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
|
|
WO2002028905A2
(fr)
|
2000-10-02 |
2002-04-11 |
Chiron Corporation |
Anticorps humains anti-cd40
|
|
DE10050935A1
(de)
|
2000-10-11 |
2002-05-02 |
Tegenero Gmbh |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
|
|
US8501471B2
(en)
|
2000-10-18 |
2013-08-06 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
CA2423843A1
(fr)
|
2000-10-18 |
2002-04-25 |
Sloan-Kettering Institute For Cancer Research |
Utilisations d'anticorps monoclonal 8h9
|
|
WO2003075846A2
(fr)
|
2002-03-08 |
2003-09-18 |
Sloan-Kettering Institute For Cancer Research |
Utilisations d'anticorps 8h9 monoclonaux
|
|
US8414892B2
(en)
|
2000-10-18 |
2013-04-09 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
US20020102264A1
(en)
|
2000-10-18 |
2002-08-01 |
Cheung Nai-Kong V. |
Uses of monoclonal antibody 8H9
|
|
CN1272345C
(zh)
|
2000-12-14 |
2006-08-30 |
安斯泰来制药有限公司 |
沉默型抗cd－28抗体及其应用
|
|
ES2353273T3
(es)
|
2000-12-26 |
2011-02-28 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anticuerpos anti-cd28.
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
EP2011802A3
(fr)
|
2001-04-27 |
2009-04-15 |
Kyowa Hakko Kirin Co., Ltd. |
Anticorps monoclonal anti-CD40
|
|
WO2003028712A2
(fr)
*
|
2001-09-28 |
2003-04-10 |
Universite Libre De Bruxelles |
Agonistes de recepteur purinergique et pyrimidinergique pour le traitement de maladies immunitaires mediees par le lymphocyte t cd4+ active
|
|
WO2003029296A1
(fr)
|
2001-10-02 |
2003-04-10 |
Chiron Corporation |
Anticorps humains diriges contre le cd40
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
PA8557501A1
(es)
|
2001-11-12 |
2003-06-30 |
Pfizer Prod Inc |
Benzamida, heteroarilamida y amidas inversas
|
|
AU2002346581A1
(en)
|
2001-11-26 |
2003-06-10 |
Chiron Corporation |
Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
DE10212108A1
(de)
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
NZ536746A
(en)
|
2002-06-13 |
2007-02-23 |
Crucell Holland Bv |
An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
|
|
DE10230223A1
(de)
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
|
US7052694B2
(en)
|
2002-07-16 |
2006-05-30 |
Mayo Foundation For Medical Education And Research |
Dendritic cell potentiation
|
|
AU2003259294A1
(en)
|
2002-07-30 |
2004-02-16 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
AU2003294462C1
(en)
|
2002-11-21 |
2011-06-30 |
University Of Utah Research Foundation |
Purinergic modulation of smell
|
|
WO2004056875A1
(fr)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Anticorps anti pd-1 et utilisations
|
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
|
AU2004244626A1
(en)
|
2003-05-23 |
2004-12-09 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
GB0324498D0
(en)
|
2003-07-21 |
2003-11-26 |
Aventis Pharma Inc |
Heterocyclic compounds as P2X7 ion channel blockers
|
|
EP1600164A3
(fr)
|
2003-09-22 |
2006-05-17 |
TeGenero AG |
Utilisation d'une substance liant le CD28 dans la production d'une composition pharmaceutique à effet dose-dépendant
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
WO2005041892A2
(fr)
|
2003-11-03 |
2005-05-12 |
Cornell Research Foundation, Inc |
Inhibition du recepteur des purines en tant que strategie therapeutique au niveau de la moelle epiniere et du cerveau
|
|
ES2346978T3
(es)
|
2003-11-04 |
2010-10-22 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
WO2005044307A2
(fr)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Procedes de therapie pour des cancers lies a la cellule b
|
|
JP4746552B2
(ja)
|
2003-11-04 |
2011-08-10 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
|
|
SI1680141T1
(sl)
|
2003-11-04 |
2010-12-31 |
Novartis Vaccines & Diagnostic |
Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen
|
|
CA2544364A1
(fr)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Utilisation d'anticorps anti-cd40 antagonistes pour le traitement de la leucemie lymphocytique chronique
|
|
DE10352900A1
(de)
|
2003-11-11 |
2005-06-16 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
KR101223373B1
(ko)
|
2003-12-25 |
2013-01-16 |
교와 핫꼬 기린 가부시키가이샤 |
항 ｃｄ４０ 항체의 변이체
|
|
WO2005111003A1
(fr)
|
2004-04-29 |
2005-11-24 |
Abbott Laboratories |
Analogues d’amino-tétrazoles et méthodes d’utilisation
|
|
US20050261239A1
(en)
*
|
2004-05-23 |
2005-11-24 |
Universiteit Van Maastricht |
Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
|
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
|
WO2006003179A2
(fr)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Anticorps anti-kir humains
|
|
JP5112863B2
(ja)
|
2004-07-01 |
2013-01-09 |
ノヴォ ノルディスク アー／エス |
ヒト抗−ｋｉｒ抗体
|
|
US20080057070A1
(en)
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
WO2006072625A2
(fr)
|
2005-01-06 |
2006-07-13 |
Novo Nordisk A/S |
Procedes et traitements combines anti-kir
|
|
ES2374603T3
(es)
|
2005-01-06 |
2012-02-20 |
Novo Nordisk A/S |
Agentes de unión a kir y procedimientos de uso de los mismos.
|
|
JP5154949B2
(ja)
|
2005-01-06 |
2013-02-27 |
ノヴォ ノルディスク アー／エス |
ウイルス感染を治療するための組成物および方法
|
|
US8323645B2
(en)
|
2005-03-24 |
2012-12-04 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
US20060240006A1
(en)
|
2005-04-20 |
2006-10-26 |
Chishih Chu |
Novel antibody structures derived from human germline sequences
|
|
EP1874823B1
(fr)
|
2005-04-27 |
2016-01-13 |
Indiana University Research and Technology Corporation |
Anticorps de l'isoforme de l'antigene nucleaire des cellules proliferatives cancereuses specifiques (pcnacs) et leurs utilisations
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
US7585960B2
(en)
|
2005-05-11 |
2009-09-08 |
Theramab Gmbh |
Nucleic acids encoding superagonistic anti-CD28 antibodies
|
|
JP5208730B2
(ja)
|
2005-05-18 |
2013-06-12 |
ノバルティス アーゲー |
Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法
|
|
PL1889065T3
(pl)
|
2005-05-18 |
2013-12-31 |
Novartis Ag |
Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
|
|
KR100694508B1
(ko)
|
2005-05-24 |
2007-03-13 |
울산대학교 산학협력단 |
Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
|
|
EP1885399B1
(fr)
|
2005-05-26 |
2010-10-20 |
Seattle Genetics, Inc. |
Anticorps anti-cd40 humanisés et procédés d'utilisation
|
|
CA2612241C
(fr)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
|
|
JP2009517339A
(ja)
|
2005-11-01 |
2009-04-30 |
ノバルティス アーゲー |
抗ｃｄ４０抗体の使用
|
|
JP2009513712A
(ja)
|
2005-11-01 |
2009-04-02 |
ノバルティス アーゲー |
抗ｃｄ４０抗体の使用
|
|
CN101304981A
(zh)
|
2005-11-07 |
2008-11-12 |
艾博特公司 |
P2x7受体拮抗剂及使用方法
|
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
|
|
NZ568015A
(en)
|
2005-12-08 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to O8E
|
|
AU2006329944A1
(en)
|
2005-12-09 |
2007-07-05 |
Seattle Genetics, Inc. |
Methods of using CD40 binding agents
|
|
US20110008368A1
(en)
|
2006-01-13 |
2011-01-13 |
Board Of Regents, The University Of Texas System |
Methods of modulating the ox40 receptor to treat cancer
|
|
US20100184802A1
(en)
|
2006-03-16 |
2010-07-22 |
Kelly Michael G |
Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof
|
|
GEP20125628B
(en)
|
2006-04-21 |
2012-09-10 |
Novartis Ag |
Pharmaceutical compositions containing antagonist anti-cd40 antibody
|
|
EP1854810A1
(fr)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
|
|
KR100745488B1
(ko)
|
2006-07-04 |
2007-08-02 |
학교법인 울산공업학원 |
항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
|
|
US8067550B2
(en)
|
2006-10-10 |
2011-11-29 |
Biosceptre International Limited |
Hybridomas producing antibodies against non functional P2X7 receptor
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
AU2007334264A1
(en)
|
2006-11-15 |
2008-06-26 |
Medarex, Inc. |
Human monoclonal antibodies to BTLA and methods of use
|
|
US20100189723A1
(en)
|
2007-01-11 |
2010-07-29 |
Peter Andreas Nicolai Reumert Wagtmann |
Anti-kir antibodies, formulations, and uses thereof
|
|
JP5357778B2
(ja)
|
2007-01-23 |
2013-12-04 |
ゼンコー・インコーポレイテッド |
最適化ｃｄ４０抗体および前記を使用する方法
|
|
EP2121008A4
(fr)
|
2007-03-22 |
2010-03-31 |
Sloan Kettering Inst Cancer |
Utilisations de l'anticorps monoclonal 8h9
|
|
WO2008114002A1
(fr)
|
2007-03-22 |
2008-09-25 |
Astrazeneca Ab |
Dérivés de quinoléine destinés au traitement de maladies inflammatoires
|
|
MX2009010759A
(es)
|
2007-04-03 |
2009-10-28 |
Glaxo Group Ltd |
Derivados de carboxamida imidazolidina como modulares de p2x7.
|
|
AU2008236649B2
(en)
|
2007-04-10 |
2013-05-02 |
H. Lundbeck A/S |
Heteroaryl amide analogues as P2X7 antagonists
|
|
EP2703011A3
(fr)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anticorps anti-ICOS et leur utilisation dans le traitement de l'oncologie, la transplantation et les maladies auto-immunes
|
|
WO2008138876A1
(fr)
|
2007-05-10 |
2008-11-20 |
Glaxo Group Limited |
Dérivés du pyrazole utilisés comme modulateurs de p2x7
|
|
KR20080107050A
(ko)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
|
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
WO2009001673A1
(fr)
*
|
2007-06-26 |
2008-12-31 |
Josai University Corporation |
Immunoadjuvant contenant de l'atp
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
FR2921342B1
(fr)
|
2007-09-20 |
2010-03-12 |
Airbus France |
Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
|
|
JP2011500767A
(ja)
|
2007-10-26 |
2011-01-06 |
グラクソ グループ リミテッド |
Ｐ２ｘ７モジュレータとしての４−ベンゾイル−１−置換ピペラジン−２−オン誘導体
|
|
CA2699631A1
(fr)
|
2007-10-31 |
2009-05-07 |
Nissan Chemical Industries, Ltd. |
Derives de pyridazinone et leur utilisation comme inhibiteurs du recepteur p2x7
|
|
CN101970003A
(zh)
|
2007-11-09 |
2011-02-09 |
诺华有限公司 |
抗cd40抗体的应用
|
|
US8106073B2
(en)
|
2007-11-30 |
2012-01-31 |
Astrazeneca Ab |
Quinoline derivatives 057
|
|
AR069747A1
(es)
|
2007-11-30 |
2010-02-17 |
Medarex Inc |
Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
|
|
CN102006890A
(zh)
|
2007-12-04 |
2011-04-06 |
阿尔尼拉姆医药品有限公司 |
靶向脂质
|
|
EP2245065A1
(fr)
|
2008-01-23 |
2010-11-03 |
Xencor, Inc. |
Anticorps dirigés contre cd40 optimisés et leurs procédés d'utilisation
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
US8314068B2
(en)
|
2008-04-14 |
2012-11-20 |
University Hospitals Of Cleveland |
P2X7 inhibition of epithelial cancers and papillomas
|
|
KR101598397B1
(ko)
|
2008-04-22 |
2016-02-29 |
얀센 파마슈티카 엔.브이. |
퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
|
|
EP2279003A4
(fr)
|
2008-05-01 |
2013-04-03 |
Gtc Biotherapeutics Inc |
Anticorps anti-cd137 en tant qu'agent dans le traitement d'états inflammatoires
|
|
CA2729567C
(fr)
|
2008-06-30 |
2018-04-24 |
Kyowa Hakko Kirin Co., Ltd. |
Anticorps anti-cd27
|
|
KR20110036618A
(ko)
|
2008-07-16 |
2011-04-07 |
베일러 리서치 인스티튜트 |
극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신
|
|
US8518410B2
(en)
|
2009-03-10 |
2013-08-27 |
Baylor Research Institute |
Fusion protein with HIV antigen
|
|
AR073459A1
(es)
|
2008-07-18 |
2010-11-10 |
Domantis Ltd |
Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
|
|
EP2700651B1
(fr)
|
2008-07-18 |
2019-04-10 |
Bristol-Myers Squibb Company |
Compositions monovalentes pour la liaison au CD28 et procédés d'utilisation
|
|
US20110097339A1
(en)
|
2008-07-18 |
2011-04-28 |
Domantis Limited |
Compositions monovalent for CD28 binding and methods of use
|
|
JP5794917B2
(ja)
|
2008-09-12 |
2015-10-14 |
アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ |
Ｐｄ−１特異抗体およびその使用
|
|
CA2736829C
(fr)
|
2008-09-12 |
2018-02-27 |
Isis Innovation Limited |
Anticorps specifiques de pd-1 et leurs utilisations
|
|
PL2342226T3
(pl)
|
2008-09-26 |
2017-01-31 |
Dana-Farber Cancer Institute, Inc. |
Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
|
|
WO2010042433A1
(fr)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
|
|
EP2367553B1
(fr)
|
2008-12-05 |
2017-05-03 |
Novo Nordisk A/S |
Traitement combiné pour améliorer la cytotoxicité induite par les cellules nk
|
|
EP4209510B1
(fr)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
|
|
EP2198873A1
(fr)
|
2008-12-18 |
2010-06-23 |
Aposcience AG |
Préparation pharmaceutique renfermant le surnageant de cultures de cellules mononucléaires sanguines
|
|
BRPI1008692B8
(pt)
|
2009-02-17 |
2021-05-25 |
Ucb Biopharma Sprl |
anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
AU2010222942B2
(en)
|
2009-03-10 |
2013-01-10 |
Baylor Research Institute |
Anti-CD40 antibodies and uses thereof
|
|
GB0906274D0
(en)
|
2009-04-09 |
2009-05-20 |
Ge Healthcare Ltd |
Imaging the central nervous system
|
|
ES2571235T3
(es)
|
2009-04-10 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
|
|
EP2993188B1
(fr)
|
2009-04-20 |
2020-08-19 |
Kyowa Kirin Co., Ltd. |
Anticorps anti-cd40 comprenant une igg2 ayant trois acide aminés mutés
|
|
US8501946B2
(en)
|
2009-04-29 |
2013-08-06 |
Glaxo Group Limited |
5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators
|
|
GB0907515D0
(en)
|
2009-04-30 |
2009-06-10 |
Glaxo Group Ltd |
Compounds
|
|
WO2010132389A2
(fr)
|
2009-05-14 |
2010-11-18 |
University Of Maryland, Baltimore |
Procédés de traitement de cancers et de maladies associées à l'expression de 4-1bb (cd137)
|
|
ES2352780B2
(es)
*
|
2009-06-04 |
2011-09-15 |
Laboratorios Ovejero S.A. |
Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
|
|
CA2768396A1
(fr)
|
2009-07-30 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Amides de dihydropyrimidone utilises comme modulateurs p2x7
|
|
IN2012DN00863A
(fr)
|
2009-07-31 |
2015-07-10 |
Medarex Inc |
|
|
PT3023438T
(pt)
|
2009-09-03 |
2020-05-08 |
Merck Sharp & Dohme |
Anticorpos anti-gitr
|
|
WO2011031063A2
(fr)
|
2009-09-09 |
2011-03-17 |
울산대학교 산학협력단 |
Composition de prévention ou de traitement de troubles métaboliques contenant l'anticorps anti-4-1bb
|
|
US8871760B2
(en)
|
2009-09-21 |
2014-10-28 |
Roche Palo Alto Llc |
[1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
|
|
GB0919594D0
(en)
|
2009-11-09 |
2009-12-23 |
Glaxo Group Ltd |
Compounds
|
|
NO2504364T3
(fr)
|
2009-11-24 |
2018-01-06 |
|
|
|
CA2781311C
(fr)
|
2009-12-07 |
2019-03-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methodes d'amplification d'un traitement a base d'anticorps anticancereux
|
|
ES2705015T3
(es)
|
2009-12-29 |
2019-03-21 |
Kyowa Hakko Kirin Co Ltd |
Anticuerpo anti-CD27
|
|
KR20110085038A
(ko)
|
2010-01-19 |
2011-07-27 |
울산대학교 산학협력단 |
항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
|
|
WO2011091078A2
(fr)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Variants d'anticorps possédant une activité complémentaire accrue
|
|
US8785604B2
(en)
|
2010-02-18 |
2014-07-22 |
Effimune |
Anti-CD28 humanized antibodies
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
PH12018501083A1
(en)
|
2010-03-04 |
2019-02-18 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
NZ602020A
(en)
|
2010-03-31 |
2014-05-30 |
Boehringer Ingelheim Int |
Anti-cd40 antibodies
|
|
US9028830B2
(en)
|
2010-04-08 |
2015-05-12 |
JN Biosciences, LLC |
Antibodies to CD122
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
|
JP5513242B2
(ja)
|
2010-04-28 |
2014-06-04 |
オリンパス株式会社 |
撮像装置
|
|
WO2011155607A1
(fr)
|
2010-06-11 |
2011-12-15 |
協和発酵キリン株式会社 |
Anticorps anti-tim-3
|
|
JP6023706B2
(ja)
|
2010-07-09 |
2016-11-09 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． |
Ｃｄ２７に対するアゴニスト抗体
|
|
WO2012027328A2
(fr)
|
2010-08-23 |
2012-03-01 |
Board Of Regents, The University Of Texas System |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
|
SG10201912092VA
(en)
|
2010-09-09 |
2020-02-27 |
Pfizer |
4-1bb binding molecules
|
|
JP2013249256A
(ja)
|
2010-09-15 |
2013-12-12 |
Astellas Pharma Inc |
脂肪性肝疾患治療薬
|
|
CA2812046A1
(fr)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Agents a base d'arni modifies
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
BR112013012138B1
(pt)
|
2010-11-22 |
2022-02-22 |
Innate Pharma Sa |
Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
|
|
WO2012075111A1
(fr)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
|
|
US20120149718A1
(en)
|
2010-12-14 |
2012-06-14 |
Brotherton-Pleiss Christine E |
Amido Compounds
|
|
US20120157494A1
(en)
|
2010-12-16 |
2012-06-21 |
Harris Iii Ralph New |
Isoindolyl compounds
|
|
CA2824278C
(fr)
|
2010-12-20 |
2022-09-20 |
The Rockefeller University |
Modulation d'anticorps agonistes anti-tnfr
|
|
WO2012109238A2
(fr)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
|
|
JP5458188B2
(ja)
|
2011-02-17 |
2014-04-02 |
協和発酵キリン株式会社 |
抗ｃｄ４０抗体の高濃度製剤
|
|
WO2012114268A1
(fr)
|
2011-02-22 |
2012-08-30 |
Actelion Pharmaceuticals Ltd |
Dérivés de benzamide en tant qu'antagonistes du récepteur p2x7
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
PT2683406T
(pt)
|
2011-03-11 |
2019-07-08 |
Beth Israel Deaconess Medical Ct Inc |
Anticorpos anti-cd40 e utilização dos mesmos
|
|
MX373443B
(es)
|
2011-03-31 |
2020-05-20 |
Inst Nat Sante Rech Med |
Anticuerpos dirigidos contra icos y usos de los mismos.
|
|
EP2699598B1
(fr)
|
2011-04-19 |
2019-03-06 |
Pfizer Inc |
Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
|
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
US9475879B2
(en)
|
2011-04-21 |
2016-10-25 |
Bristol-Myers Squibb Company |
Antibody polypeptides that antagonize CD40
|
|
KR102030987B1
(ko)
|
2011-04-25 |
2019-11-11 |
다이이찌 산쿄 가부시키가이샤 |
항 ｂ７-ｈ３항체
|
|
CA2833806A1
(fr)
|
2011-04-28 |
2012-11-01 |
Claire Mitchell |
Methode de traitement d'une degenerescence maculaire par la modulation des recepteurs p2y12 ou p2x7
|
|
ES2709654T3
(es)
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
|
ES2765874T3
(es)
|
2011-05-25 |
2020-06-11 |
Innate Pharma Sa |
Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
|
|
BR112013033974A2
(pt)
|
2011-07-01 |
2017-02-14 |
Biosceptre Int Ltd |
terapia de combinação
|
|
WO2013006490A2
(fr)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Anticorps se liant spécifiquement à tim3
|
|
HRP20180858T1
(hr)
|
2011-07-11 |
2018-09-21 |
Glenmark Pharmaceuticals S.A. |
Protutijela koja se vežu na ox40 i njihove uporabe
|
|
KR101995088B1
(ko)
|
2011-07-22 |
2019-07-02 |
이도르시아 파마슈티컬스 리미티드 |
Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
|
|
WO2013025779A1
(fr)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anticorps anti-b7-h4 et leurs utilisations
|
|
KR101685262B1
(ko)
|
2011-08-23 |
2016-12-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-ｏｘ４０ 항체 및 이의 사용 방법
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
WO2013039954A1
(fr)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anticorps anti-gitr
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
EP2604265A1
(fr)
|
2011-12-17 |
2013-06-19 |
Royal College of Surgeons in Ireland (RCSI) |
Antagonistes P2x7 en tant que traitement auxiliaire ou principal contre l'état de mal épileptique
|
|
BR122020002414B1
(pt)
|
2012-03-15 |
2022-03-03 |
Janssen Biotech, Inc |
Uso de anticorpos anti-cd27 humanos
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AU2013267161A1
(en)
|
2012-05-31 |
2014-11-20 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
KR101549637B1
(ko)
|
2012-06-08 |
2015-09-03 |
국립암센터 |
신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도
|
|
NZ702392A
(en)
|
2012-06-08 |
2017-03-31 |
Aduro Biotech |
Compositions and methods for cancer immunotherapy
|
|
US9268936B2
(en)
|
2012-07-27 |
2016-02-23 |
Mandiant, Llc |
Physical memory forensics system and method
|
|
WO2014022758A1
(fr)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Anticorps de liaison double à agent unique anti-pd-l1 et pd-l2 et procédés d'utilisation
|
|
EP2892928B1
(fr)
|
2012-09-03 |
2018-05-30 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Anticorps anti-icos pour traiter la maladie du greffon contre l'hôte
|
|
LT2904011T
(lt)
|
2012-10-02 |
2017-11-10 |
Bristol-Myers Squibb Company |
Anti-kir antikūnų ir anti-pd-1 antikūnų derinys, akirtas vėžio gydymui
|
|
WO2014057687A1
(fr)
|
2012-10-11 |
2014-04-17 |
第一三共株式会社 |
Conjugué anticorps-médicament
|
|
TWI598325B
(zh)
|
2012-10-12 |
2017-09-11 |
Ｈ 朗德貝克公司 |
苯甲醯胺類
|
|
TW201427947A
(zh)
|
2012-10-12 |
2014-07-16 |
Lundbeck & Co As H |
環狀胺
|
|
WO2014061277A1
(fr)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile
|
|
US9789182B2
(en)
|
2012-10-23 |
2017-10-17 |
Bristol-Myers Squibb Company |
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
|
|
JPWO2014065402A1
(ja)
|
2012-10-26 |
2016-09-08 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
JP2016011258A
(ja)
|
2012-10-26 |
2016-01-21 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
CN104918957B
(zh)
|
2012-10-30 |
2018-11-16 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
US20150297623A1
(en)
*
|
2012-11-06 |
2015-10-22 |
The Board Of Regents Of The University Of Texas System |
Methods for treatment of primary cancer and cancer metastasis
|
|
EA201590396A1
(ru)
|
2012-12-13 |
2015-12-30 |
Адуро Биотек, Инк. |
Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
|
|
US9556117B2
(en)
|
2012-12-18 |
2017-01-31 |
Actelion Pharmaceuticals Ltd. |
Indole carboxamide derivatives as P2X7 receptor antagonists
|
|
JP2016509582A
(ja)
|
2012-12-19 |
2016-03-31 |
アンプリミューン， インコーポレイテッド |
抗ヒトｂ７−ｈ４抗体およびその使用
|
|
PT2934598T
(pt)
*
|
2012-12-19 |
2018-07-24 |
Univ Texas |
Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
KR102222220B1
(ko)
|
2013-01-22 |
2021-03-03 |
이도르시아 파마슈티컬스 리미티드 |
Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
|
|
TWI599567B
(zh)
|
2013-03-14 |
2017-09-21 |
健生藥品公司 |
Ｐ２ｘ７調節劑
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
US9040534B2
(en)
|
2013-03-14 |
2015-05-26 |
Janssen Pharmaceutica Nv |
[1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
|
|
TWI627174B
(zh)
|
2013-03-14 |
2018-06-21 |
比利時商健生藥品公司 |
Ｐ２ｘ７調控劑
|
|
EP3299391B1
(fr)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anticorps et immunoconjugués anti-b7-h4
|
|
EP2970271B1
(fr)
|
2013-03-14 |
2017-11-08 |
Janssen Pharmaceutica NV |
Modulateurs de p2x7
|
|
US20140322236A1
(en)
|
2013-03-15 |
2014-10-30 |
Sdix, Llc |
Anti-human adora2a antibodies
|
|
WO2014140374A2
(fr)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Anticorps monovalents anti-cd27
|
|
MD20180107A2
(ro)
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
|
US20160084839A1
(en)
|
2013-04-02 |
2016-03-24 |
Marisa Dolled-Filhart |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
|
ME03586B
(fr)
|
2013-05-18 |
2020-07-20 |
Univ California |
Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
|
|
MX376808B
(es)
|
2013-05-24 |
2025-03-07 |
Medimmune Llc |
Anticuerpos anti-b7-h5 y sus usos.
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
SG10201708143QA
(en)
|
2013-06-06 |
2017-11-29 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
WO2014209168A1
(fr)
|
2013-06-24 |
2014-12-31 |
Kim Ruslan Zynsonovich |
Communicateur automobile
|
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
RU2016107426A
(ru)
|
2013-08-02 |
2017-09-07 |
Адуро Байотек Холдингс, Юроуп Б.В. |
Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
WO2015036394A1
(fr)
|
2013-09-10 |
2015-03-19 |
Medimmune Limited |
Anticorps contre pd-1 et leurs utilisations
|
|
EP3060056A4
(fr)
*
|
2013-10-21 |
2017-10-18 |
Drexel University |
Utilisation d'agonistes de sting pour traiter une infection chronique par le virus de l'hépatite b
|
|
ES2707057T3
(es)
|
2013-11-06 |
2019-04-02 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
|
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
WO2015091655A1
(fr)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Polythérapie avec un anticorps anti-ang 2 et un agoniste cd40
|
|
ES2783026T3
(es)
|
2014-02-04 |
2020-09-16 |
Pfizer |
Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
|
|
EP2905282A1
(fr)
|
2014-02-05 |
2015-08-12 |
AXXAM S.p.A. |
Thiazole ou oxazole substituée en tant qu'antagonistes du récepteur P2X7
|
|
WO2015134988A1
(fr)
|
2014-03-07 |
2015-09-11 |
Bristol-Myers Squibb Company |
Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
|
|
MX2016015181A
(es)
|
2014-05-21 |
2017-05-25 |
Pfizer |
Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
|
|
DK3148579T3
(da)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
|
|
WO2015181267A1
(fr)
|
2014-05-29 |
2015-12-03 |
Spring Bioscience Corporation |
Anticorps anti-b7-h3 et leurs utilisations diagnostiques
|
|
AU2015271709B2
(en)
|
2014-06-06 |
2020-11-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
WO2015188047A1
(fr)
|
2014-06-06 |
2015-12-10 |
University Of Maryland, Baltimore |
Anticorps monoclonaux anti-cd-137 présentant des capacités de liaison distinctes au fcγr pour le traitement d'un cancer ou d'une auto-immunité
|
|
WO2015198147A1
(fr)
|
2014-06-23 |
2015-12-30 |
Theramab Llc |
Compositions et méthodes pour une immunothérapie efficace et sûre
|
|
CN106659852A
(zh)
|
2014-07-09 |
2017-05-10 |
诺和诺德股份有限公司 |
机动化药物输送装置
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
KR102443258B1
(ko)
|
2014-08-12 |
2022-09-14 |
엘리게이터 바이오사이언스 에이비 |
항 cd40 항체에 의한 병용 치료제
|
|
RU2017108173A
(ru)
|
2014-08-14 |
2018-09-17 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
|
|
US20170233485A1
(en)
|
2014-08-18 |
2017-08-17 |
Biogen Ma Inc. |
Anti-cd40 antibodies and uses thereof
|
|
US20170247455A1
(en)
|
2014-08-22 |
2017-08-31 |
Bristol-Myers Squibb Company |
Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
|
|
AU2015306621B2
(en)
|
2014-08-27 |
2021-05-06 |
Memorial Sloan Kettering Cancer Center |
Antibodies, compositions, and uses
|
|
CA2951604A1
(fr)
|
2014-08-29 |
2016-03-03 |
Pablo Umana |
Therapie combinatoire d'immunocytokines a variant de l'il -2 ciblees therapie tumorale et d'anticorps anti-pd-l1 humaine
|
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
|
RU2017115315A
(ru)
|
2014-10-03 |
2018-11-08 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
AU2015340056A1
(en)
|
2014-10-27 |
2017-05-25 |
Agency For Science, Technology And Research |
Anti-TIM-3 antibodies
|
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
ES2772307T3
(es)
|
2014-10-28 |
2020-07-07 |
Childrens Univ Hospital Tuebingen |
Tratamiento de pacientes pediátricos con LLA-PCB con un anticuerpo anti-kir
|
|
HUE054075T2
(hu)
|
2014-10-29 |
2021-08-30 |
Seagen Inc |
CD40 elleni nem fukozilált antitestek adagolása és bevitele
|
|
WO2016070001A1
(fr)
|
2014-10-31 |
2016-05-06 |
Jounce Therapeutics, Inc. |
Méthodes de traitement d'états pathologiques avec des anticorps qui se lient à b7-h4
|
|
ES2763548T3
(es)
|
2014-11-06 |
2020-05-29 |
Hoffmann La Roche |
Anticuerpos anti-TIM3 y procedimientos de uso
|
|
WO2016094837A2
(fr)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anticorps anti-c10orf54 et leurs utilisations
|
|
ES2764178T3
(es)
|
2014-12-16 |
2020-06-02 |
Kayla Therapeutics |
Dinucleótidos cíclicos fluorados para inducción de citocinas
|
|
US20170340658A1
(en)
|
2014-12-16 |
2017-11-30 |
Invivogen |
Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
|
|
WO2016106004A1
(fr)
|
2014-12-23 |
2016-06-30 |
Full Spectrum Genetics, Inc. |
Nouveaux composés de liaison anti-b7h3 et leurs utilisations
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
JO3746B1
(ar)
|
2015-03-10 |
2021-01-31 |
Aduro Biotech Inc |
تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
|
|
EP3685830A1
(fr)
*
|
2015-05-20 |
2020-07-29 |
Institut National De La Sante Et De La Recherche Medicale - Inserm |
Procédés et composition pharmaceutique pour moduler la polarisation et l'activation de macrophages
|
|
MX2018001814A
(es)
|
2015-08-13 |
2018-05-07 |
Merck Sharp & Dohme |
Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
|
|
UY36969A
(es)
|
2015-10-28 |
2017-05-31 |
Novartis Ag |
Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
|
|
EP3386536A4
(fr)
|
2015-12-07 |
2019-07-31 |
Opi Vi- IP Holdco LLC |
Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
|
|
WO2017123657A1
(fr)
|
2016-01-11 |
2017-07-20 |
Gary Glick |
Dinucléotides cycliques pour traiter des affections associées à l'activité sting comme le cancer
|
|
US20190062272A1
(en)
|
2016-04-13 |
2019-02-28 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
|
EP3507367A4
(fr)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
|
|
WO2018045204A1
(fr)
|
2016-08-31 |
2018-03-08 |
Ifm Therapeutics, Inc |
Analogues de dinucléotides cycliques pour traiter des états associés à l'activité de la piqûre (stimulateur des gènes de l'interféron)
|
|
US10414747B2
(en)
|
2016-10-04 |
2019-09-17 |
Merck Sharp & Dohme Corp. |
Benzo[b]thiophene compounds as sting agonists
|
|
JOP20170188A1
(ar)
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
|
PT3512861T
(pt)
|
2016-12-01 |
2021-04-29 |
Takeda Pharmaceuticals Co |
Dinucleotídeos cíclicos
|
|
AU2017378782A1
(en)
|
2016-12-20 |
2019-07-04 |
Merck Sharp & Dohme Corp. |
Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
|
|
AU2017378783A1
(en)
|
2016-12-20 |
2019-07-04 |
Merck Sharp & Dohme Corp. |
Cyclic dinucleotide sting agonists for cancer treatment
|
|
US11492367B2
(en)
|
2017-01-27 |
2022-11-08 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
JP7213188B2
(ja)
|
2017-01-27 |
2023-01-26 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
AR113224A1
(es)
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
WO2018208667A1
(fr)
|
2017-05-12 |
2018-11-15 |
Merck Sharp & Dohme Corp. |
Composés dinucléotidiques cycliques en tant qu'agonistes sting
|
|
JP2020524718A
(ja)
|
2017-06-22 |
2020-08-20 |
キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ |
ヒトｓｔｉｎｇの複素環式小分子調節因子
|
|
JP2020524717A
(ja)
|
2017-06-22 |
2020-08-20 |
キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ |
ヒトｓｔｉｎｇの小分子調節因子
|
|
CA3067257A1
(fr)
|
2017-06-22 |
2018-12-27 |
Curadev Pharma Limited |
Modulateurs a petites molecules de sting humain
|
|
JP2020530838A
(ja)
|
2017-08-04 |
2020-10-29 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
|
|
AU2018311965A1
(en)
|
2017-08-04 |
2020-02-13 |
Merck Sharp & Dohme Llc |
Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
|
|
CN107335049B
(zh)
*
|
2017-08-18 |
2019-10-18 |
中国药科大学 |
菊科类型环肽化合物作为cGAS-STING信号通路抑制剂的应用
|
|
US11638716B2
(en)
|
2017-08-31 |
2023-05-02 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
WO2019051489A1
(fr)
|
2017-09-11 |
2019-03-14 |
Sperovie Biosciences, Inc. |
Composés, compositions et méthodes de traitement de maladie
|
|
WO2019055750A1
(fr)
|
2017-09-15 |
2019-03-21 |
Aduro Biotech, Inc. |
Composés de pyrazolopyrimidinone et leurs utilisations
|
|
EP3692033A1
(fr)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulateurs de stimulateur des gènes (sting) d'interféron utiles dans le traitement du vih
|
|
WO2019069275A1
(fr)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Méthodes d'administration d'agonistes de sting
|